Who Is Eligible for Hemophilia A Gene Therapy Treatment?

Gene therapy is a major advancement in hemophilia A treatment, offering the possibility of a “functional cure.” For many patients, the idea of a single treatment that reduces the need for regular infusions is highly appealing. However, gene therapy is currently approved only for a specific group of patients, and it comes with strict eligibility criteria and rigorous long-term monitoring requirements.

This page provides a high-level overview of the key eligibility criteria based on FDA and EMA approvals for valoctocogene roxaparvovec (Roctavian). Final eligibility is always determined by a specialized hemophilia treatment center following a comprehensive medical evaluation.

What is a “Functional Cure”?

When doctors talk about a “functional cure” in hemophilia A, it does not mean your genetics are permanently fixed or that your factor VIII (FVIII) levels will return to normal. Instead, it means the gene therapy establishes continuous, natural production of factor VIII inside your body ^[1]. Even modest increases in your factor VIII levels can transform a severe bleeding phenotype into a much milder one, which can significantly reduce your bleeding rates and often reduces the need for regular prophylactic infusions ^[2][3].

However, it is crucial to set realistic expectations:

• Variability: The amount of factor VIII produced varies significantly from person to person.
• Potential Decline: Studies have shown that factor VIII expression can gradually decline over time after treatment ^[4].
• Return to Prophylaxis: While many people can stop regular prophylaxis, some individuals may eventually see their factor levels drop enough that they need to resume treatment ^[5][6].
• Do Not Stop Early: You should never stop your prescribed prophylaxis after receiving gene therapy until your treatment center explicitly confirms your factor levels are adequate and provides a new bleed-management plan. Breakthrough bleeding is still possible.

Key Eligibility Criteria (FDA/EMA)

Currently, the primary gene therapy approved for hemophilia A is valoctocogene roxaparvovec (Roctavian) ^[7][8]. Because of how the therapy is administered and the medical risks involved, eligibility is strict. To be considered, you generally must meet criteria including:

• Age: You must be an adult, aged 18 years or older ^[7][8].
• Severity: You must have severe congenital hemophilia A. In clinical trials and regulatory labeling, this is typically defined as a baseline underlying factor VIII activity level of 1 IU/dL or lower ^[7][8]. Note: “Baseline” refers to your natural, underlying level; you do not need to stop your current prophylaxis to obtain this test.
• No History of Inhibitors: You must not have an active factor VIII inhibitor, nor can you have any historical record of developing inhibitors in the past ^[7][9]. Even if an inhibitor is no longer detectable today, a documented past history makes you ineligible under current approvals.
• No Pre-existing AAV5 Antibodies: The therapy uses a modified, non-replicating virus called adeno-associated virus 5 (AAV5) as a vector to deliver the new factor VIII gene. It is administered via an intravenous infusion ^[8]. If your immune system has previously been exposed to a naturally occurring AAV5 virus, you may have developed antibodies against it. Having detectable anti-AAV5 antibodies on a validated blood test is a strict exclusion criterion. This is because your immune system would likely neutralize the vector, leading to poor gene delivery and reduced or non-existent efficacy ^[8][10].

Additional Evaluations: Meeting the criteria above does not guarantee eligibility. A treatment center must also thoroughly evaluate your liver health (checking for fibrosis, cirrhosis, active hepatitis, or fatty liver disease), overall immune status, and any other medical conditions that might make the treatment unsafe for you.

Post-Treatment Considerations

If you receive gene therapy, you will need rigorous, scheduled medical follow-up.

• Liver Inflammation and Immunosuppressants: As the viral vector targets your liver cells, liver inflammation (seen as elevated liver enzymes in blood tests) is a very common side effect ^[7]. To manage this, many patients require a course of immunosuppressive medications, usually corticosteroids ^[11][12]. The dose and duration are strictly guided by your liver enzyme results. Corticosteroids carry their own risks, including increased risk of infection, mood changes, elevated blood sugar, and bone effects.
• Intensive Early Monitoring: In the first several months, you will need frequent, sometimes weekly, blood draws to closely monitor your liver function and factor VIII levels.
• Long-Term Surveillance: Over the long term, regular monitoring remains essential. Based on theoretical risks of the vector integrating into your DNA, guidelines recommend routine imaging of your liver (such as ultrasounds every 6 to 12 months) and specific blood tests to monitor for liver cancer (hepatocellular carcinoma), especially for individuals with underlying liver risk factors ^[13].

Note: In some regions, therapies like Roctavian have faced availability and market-access challenges related to healthcare system readiness and economic sustainability ^[14]. Availability may depend heavily on your location and insurance coverage.